Get the Stockscreener App
7.19
1.27%
0.09
After Hours:
7.19
Lifecore Biomedical Inc stock is traded at $7.19, with a volume of 106.76K.
It is up +1.27% in the last 24 hours and down -2.31% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$7.10
Open:
$7.09
24h Volume:
106.76K
Relative Volume:
0.65
Market Cap:
$269.17M
Revenue:
$128.45M
Net Income/Loss:
$6.54M
P/E Ratio:
143.80
EPS:
0.05
Net Cash Flow:
$-8.79M
1W Performance:
+6.05%
1M Performance:
-2.31%
6M Performance:
+6.36%
1Y Performance:
+26.58%
1-Day Range:
$6.97
$7.24
1-Week Range:
$6.61
$7.37
52-Week Range:
$4.76
$8.85
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
7.19 | 266.01M | 128.45M | 6.54M | -8.79M | 0.05 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Stock (LFCR) Latest News
Lifecore Biomedical Approves Key Proposals at Annual Meeting - TipRanks
Can Lifecore Biomedical Inc. stock weather global recessionMarket Sentiment Summary & Proven Capital Preservation Methods - newser.com
Why pension funds invest in Lifecore Biomedical Inc. (LDE) stock2025 Volume Leaders & Technical Analysis for Trade Confirmation - newser.com
Can Lifecore Biomedical Inc. stock beat market expectations this quarterMarket Activity Summary & Technical Entry and Exit Alerts - newser.com
Why millennials buy Lifecore Biomedical Inc. (LDE) stockJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
When is the best time to exit Lifecore Biomedical Inc.2025 Technical Patterns & Weekly Return Optimization Plans - newser.com
Will Lifecore Biomedical Inc. (LDE) stock recover faster than industryTake Profit & Capital Efficiency Focused Ideas - newser.com
Is Lifecore Biomedical Inc. (LDE) stock suitable for passive index fundsJuly 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
Will Lifecore Biomedical Inc. (LDE) stock gain from lower interest ratesJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
Is Lifecore Biomedical Inc. (LDE) stock undervalued after correction2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Is Lifecore Biomedical Inc. forming a reversal patternJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
What catalysts could drive Lifecore Biomedical Inc. stock higher2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Is Lifecore Biomedical Inc. stock affected by interest rate hikesIndex Update & Weekly Breakout Stock Alerts - newser.com
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - ACCESS Newswire
Here’s Why Lifecore Biomedical Inc (LFCR) Declined 22% at the End of Q3 - Insider Monkey
Will Lifecore Biomedical Inc. outperform the marketPrice Action & Precise Trade Entry Recommendations - newser.com
Key metrics from Lifecore Biomedical Inc.’s quarterly data2025 Top Gainers & Community Verified Trade Signals - newser.com
Can Lifecore Biomedical Inc. stock surprise with earnings upsidePortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
What hedge fund moves indicate for Lifecore Biomedical Inc. (LDE) stock2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Will Lifecore Biomedical Inc. (LDE) stock benefit from infrastructure billGold Moves & Short-Term Swing Trade Alerts - newser.com
Is it too late to sell Lifecore Biomedical Inc.Quarterly Profit Review & Safe Entry Trade Reports - newser.com
Lifecore signs agreement with leading global pharmaceutical company - TipRanks
Lifecore Selected as Commercial Mfg. Partner for Leading Injectable Product - Contract Pharma
Lifecore Biomedical Selects as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company - MarketScreener
What analysts say about Lifecore Biomedical Inc stockTrend Following Strategies & Outstanding Growth Portfolio - earlytimes.in
Lifecore (NASDAQ: LFCR) to transfer manufacturing; second agreement with same multinational - Stock Titan
Lifecore and PolyPeptide link for US peptide manufacturing - Yahoo Finance
Will Lifecore Biomedical Inc. (LDE) stock see insider accumulationJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Real time pattern detection on Lifecore Biomedical Inc. stockGap Down & Free High Accuracy Swing Entry Alerts - newser.com
Lifecore, PolyPeptide Partner on Peptide Manufacturing Solution for U.S. Market - Contract Pharma
What sentiment indicators say about Lifecore Biomedical Inc. stockWeekly Investment Report & Smart Investment Allocation Insights - Fundação Cultural do Pará
Lifecore, PolyPeptide collab to offer peptide manufacturing solution - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore, PolyPeptide Partner on Peptide Manufacturing for U.S. Market - Contract Pharma
Lifecore Biomedical, Inc. and Polypeptide Laboratories, Inc. Announce Collaboration Intended to Offer End-To-End Peptide Manufacturing Solution for U.S. Market - MarketScreener
Lifecore and PolyPeptide partner on integrated peptide manufacturing By Investing.com - Investing.com Nigeria
Lifecore and PolyPeptide partner on integrated peptide manufacturing - Investing.com
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market - The Manila Times
Lifecore Biomedical and PolyPeptide Laboratories Announce Collaboration to Enhance Peptide-Based Pharmaceutical Development - Quiver Quantitative
Lifecore (NASDAQ: LFCR), PolyPeptide sign U.S. DS-to-DP peptide collaboration - Stock Titan
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lifecore Biomedical Inc Stock (LFCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| English Aron R. | 10% Owner |
May 28 '25 |
Sale |
7.12 |
150,419 |
1,071,555 |
264,180 |
| English Aron R. | 10% Owner |
May 23 '25 |
Sale |
6.75 |
96,137 |
649,386 |
1,554,103 |
| English Aron R. | 10% Owner |
May 13 '25 |
Sale |
7.00 |
12,334 |
86,353 |
1,650,240 |
| English Aron R. | 10% Owner |
May 12 '25 |
Sale |
7.03 |
45,698 |
321,426 |
1,662,574 |
| English Aron R. | 10% Owner |
May 08 '25 |
Sale |
7.00 |
5,098 |
35,693 |
1,708,972 |
| English Aron R. | 10% Owner |
May 09 '25 |
Sale |
7.00 |
700 |
4,900 |
1,708,272 |
| English Aron R. | 10% Owner |
May 05 '25 |
Sale |
7.08 |
24,543 |
173,831 |
1,730,618 |
| English Aron R. | 10% Owner |
May 07 '25 |
Sale |
7.01 |
15,847 |
111,099 |
1,714,070 |
| English Aron R. | 10% Owner |
May 06 '25 |
Sale |
7.05 |
701 |
4,940 |
1,729,917 |
| Josephs Paul | Chief Executive Officer |
Jan 08 '25 |
Buy |
5.74 |
17,000 |
97,580 |
559,717 |
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):